LENZ Therapeutics (LENZ) CORRESPCorrespondence with SEC

Graphite Bio, Inc.

611 Gateway Blvd, Suite 120

South San Francisco, CA 94080

February 9, 2024

VIA EDGAR

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street NE

Washington, DC 20549

Acceleration Request for Registration Statement on Form S-4

File No. 333-275919

Dear. Ms. Gama, Mr. Drory, Mr. Atallah and Ms. Dicker:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Graphite Bio, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 13, 2024, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Andrew Goodman at (617) 570-1861. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Andrew Goodman, by email to agoodman@goodwinlaw.com or by facsimile to (212) 937-3172.

If you have any questions regarding this request, please contact Andrew Goodman of Goodwin Procter LLP at (617) 570-1861.

Maggie L. Wong, Goodwin Procter LLP

Shoaib Ghias, Goodwin Procter LLP

Tevia K. Pollard, Goodwin Procter LLP